Owen A. O’Connor, M.D., Ph.D.

Founder, Chair and Chief Executive Officer (CEO)

Owen is the Founder, Chair and Chief Executive Officer of Nouveau Biosciences. Under his leadership, Nouveau Biosciences has matured a platform to drug focused biotechnology company leveraging the latest advances in synthetic lethality screens, genomics and computational biology to produce a pipeline of novel, derisked nanotherapeutic drugs for cancer.  Their lead drug candidate, kromastat, has been shown to be a best-in-class and best-in-disease drug for the treatment of T-cell malignancies, pancreas cancer and a variety of aggressive forms of leukemia.  Nouveau has raised substantial capital to support its ambitious clinical programs, which has complimented many strategic collaborations around the world.  Dr. O’Connor is a world renowned physician-scientist who holds many patents on methods to treat cancer, and has led global regulatory approval of many drugs across a host of indications in cancer and autoimmune diseases.  Owen has studied and been on faculty at Cornell University Medical Center, Memorial Sloan Kettering Cancer Center and Columbia University to name a few. He has well over 300 publications, and has authored and edited many books on lymphoma and targeted drug therapies for cancer.  He is passionate about creating teams that think outside the box, and have a penchant for solving the field’s most significant challenges.